Topic: chronic lymphocytic leukemia
Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.
To show Brukinsa is better than AbbVie and J&J's blockbuster Imbruvica, BeiGene is running phase 3 head-to-head trials in blood cancers.
J&J enlisted British celebrity home stylist Laurence Llewelyn-Bowen to raise awareness of blood cancer and its symptoms this month.
AstraZeneca’s Calquence has been battling it out in MCL, but the company has had its eye on CLL. And that’s where it’s scored its latest win.
In May, AbbVie and Roche scored an approval for Venclexta and Gazyva in CLL. Tuesday, they rolled out the data that helped get them there.
When it comes to CLL, AZ is looking to push Imbruvica aside with newcomer Calquence. But based on some new data, one analyst doesn’t see it happening.
AbbVie and Roche’s Venclexta may have recently hit a stumbling block—but in chronic lymphocytic leukemia, it’s rolling.
Chasing big fish in the BTK inhibitor market, AstraZeneca’s Calquence was looking for a leg up. New clinical data show promise in leukemia.
Add another indication for Imbruvica in chronic lymphocytic leukemia to the list.
Just a year after approval, AZ’s Calquence is giving Imbruvica a run for its money in MCL. But the British drugmaker doesn’t want to stop there.